Opportunity type: Project cooperation

Vaccine-validated antigen/protein-loading platform for partner-defined autoimmune, CNS and oncology PoC; seeking an exclusive field partner.

Full description

EXORPHIA is developing an engineered extracellular vesicle platform that integrates antigen/protein cargo loading, surface and luminal presentation, targeting design, route selection, and EV manufacturing and quality control.

The platform’s current internal nonclinical proof-of-concept primarily supports multivalent infectious-disease vaccine applications. These studies provide platform-level validation of antigen/protein loading, EV production, immune-response evaluation, and exploratory tolerability in mice.

The current data should not be interpreted as direct efficacy proof-of-concept for autoimmune disease, CNS delivery, or oncology. These areas are positioned as partner-defined development and validation opportunities.

Potential therapeutic applications include:

1. Antigen-specific immune modulation

Disease-related antigens or proteins may be incorporated into engineered EVs to explore antigen-specific immune modulation for autoimmune or allergic diseases. This is an adjacent immune application and requires dedicated pharmacology and immune-tolerance studies.

2. CNS-DDS and rare neurology

A potential starting point is systemic intravenous administration of a single defined payload using a partner-selected BBB-targeting strategy. Dedicated evaluation of biodistribution, brain exposure, target engagement, payload-dependent PK/PD, repeat-dose tolerability, and manufacturability would be required.

The CNS concept is independent of the intranasal vaccine program and is not based on established EXORPHIA CNS-delivery efficacy data.

3. Oncology

Potential applications include antigen/protein delivery, cancer-immunotherapy concepts, and modulation of the tumor microenvironment. These are future development opportunities and are not currently positioned as validated cancer-vaccine or oncology programs.

The platform currently has direct internal validation for antigen/protein loading. Nucleic-acid payloads, including ASO, siRNA, and mRNA, remain future expansion themes requiring partner-defined loading, delivery, biodistribution, and functional validation.

We are seeking an exclusive partner in selected therapeutic applications to define the target disease, payload, targeting strategy, administration route, and target product profile.

An initial feasibility phase may be conducted under NDA to establish an application-specific proof-of-concept, followed by a program-based or field-based exclusive license.

EXORPHIA would provide the engineered EV platform, antigen/protein-loading know-how, initial vaccine-based platform PoC, access to applicable proprietary EV technology, and CMC/QC foundation. The partner would lead disease-model selection, application-specific validation, IND-enabling development, regulatory strategy, clinical development, and commercialization.